Specifically, tRFLys−CTT-010 exhibited significant upregulation in human triple-negative breast cancer (TNBC) and was found to modulate the expression of glucose-6-phosphatase catalytic subunit (G6PC), a pivotal enzyme in glucose metabolism. This evidence concerns the gene G6PC1 and triple-negative breast carcinoma.